Top Markets
#1 Black Phoenix Black Phoenix +356.02%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +55.09%
#4 Akedo Akedo +48.10%
#5 Acurast Acurast +34.81%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +27.41%
#7 BasedHype BasedHype +25.95%
#8 Avantis Avantis +23.46%
#9 Cryptopia Cryptopia +21.54%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +16.89%
Coin of the day
Black Phoenix Black Phoenix
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Histogen Inc. Histogen Inc.

Histogen Inc.

HSTO
Rang in Aktien #40870
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on... Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
Aktienkurs
$0.02765
Zuletzt synchronisiert: 2024-12-23
Marktkapitalisierung
$69.04K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Histogen Inc. (HSTO)

Kategorie

Healthcare
P/B-Verhältnis für Histogen Inc. (HSTO)
P/B-Verhältnis zum August 2026 TTM: 0.00
Laut den neuesten Finanzberichten und dem Aktienkurs von Histogen Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0.00. Am Ende des Jahres 2021 lag das P/B-Verhältnis bei 0.06.
P/B-Verlauf für Histogen Inc. von 2011 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
2026 (TTM) 0.00 -77.50%
2022 0.02 -69.01%
2021 0.06 -31.54%
2020 0.09 -168.39%
2019 -0.13 -166.48%
2018 0.19 -59.34%
2017 0.47 -13.89%
2016 0.55 -98.24%
2015 31.05 -52.41%
2014 65.25 265.13%
2013 17.87 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 139,040.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 140,973.33%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 80,655.56%
BE